



Advances in Antibody–Drug Conjugates

Guest Editor:

Prof. Dr. Bing Sun

1. Key Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China
2. School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China

Deadline for manuscript submissions:

20 April 2026

Message from the Guest Editor

Dear Colleagues,

Antibody–drug conjugates (ADCs) represent a significant advance in cancer treatment by combining the specificity of antibodies with the potency of highly cytotoxic agents. This targeted strategy has the potential to reduce the severity of side effects by preferentially delivering the therapeutic payload directly to the tumor site, with ADCs sometimes referred to as ‘precision chemotherapy’. As our understanding of tumor biology deepens and ADC design improves, we are moving closer to effective, safe, and personalized cancer therapies. Numerous innovative ADC formats are being developed, including bispecific ADCs, dual-drug ADCs, conditionally active ADCs, immunostimulatory ADCs, and antibody–siRNA conjugates. Each of these formats offers unique capabilities to tackle a range of cancer treatment challenges, bringing new hope to patients with difficult-to-treat cancers.

This Special Issue will cover all aspects of the roles and mechanisms of ADC therapeutics in cancer and non-oncology indications, focusing on recent advances in the ADC platform and technology, including targets, antibody selection, payload, and linker and conjugation chemistry.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. José L. Quiles

Department of Physiology,
Institute of Nutrition and Food
Technology “Jose Mataix”,
Biomedical Research Center,
University of Granada, Avda.
Conocimiento s/n, 18100 Armilla,
Granada, Spain

Message from the Editor-in-Chief

The *International Journal of Molecular Sciences (IJMS)* is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, and molecular biophysics. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI